



HAL
open science

Interstitial Lung Disease and Mediastinal Lymph Nodes: A Computed Tomography–based Biomarker beyond Nosological and Etiological Borders?

Alain Lescoat, Mathieu Lederlin, Alice Ballerie, Nicolas Belhomme, Catherine Cavalin, Patrick Jégo, Stephane Jouneau

► **To cite this version:**

Alain Lescoat, Mathieu Lederlin, Alice Ballerie, Nicolas Belhomme, Catherine Cavalin, et al.. Interstitial Lung Disease and Mediastinal Lymph Nodes: A Computed Tomography–based Biomarker beyond Nosological and Etiological Borders?. *American Journal of Respiratory and Critical Care Medicine*, 2019, 199 (8), pp.1038-1040. 10.1164/rccm.201811-2123LE . hal-01998531

HAL Id: hal-01998531

<https://hal-univ-rennes1.archives-ouvertes.fr/hal-01998531>

Submitted on 13 Mar 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

***ILD and mediastinal lymph nodes:
A CT-based biomarker beyond nosological and etiological borders?***

Alain Lescoat MD MSc^{1,2}, Mathieu Lederlin MD PhD^{3,4,5}, Alice Ballerie MD MSc^{1,2},
Nicolas Belhomme MD¹, Catherine Cavalin PhD^{7,8,9,10}, Patrick Jégo MD PhD^{1,2},
Stéphane Jouneau MD PhD^{2,11}

1-Department of Internal Medicine and Clinical Immunology, CHU Rennes, University of Rennes 1, Rennes, France.

2-University of Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000, Rennes, France.

3-INSERM, U1099, F-35000, Rennes, France.

4-LTISI, Université de Rennes 1, Bât. 22, Campus de Beaulieu, F-35000, Rennes, France.

5-CHU Rennes, Department of Radiology, F-35000, Rennes, France.

7-Institut de Recherche Interdisciplinaire en Sciences Sociales (IRISSO), UMR CNRS-INRA 7170-1427, Université Paris-Dauphine, Paris, France

8- Centre d'études européennes et de politique comparée de Sciences Po, Paris, France

9- Laboratoire interdisciplinaire d'évaluation des politiques publiques (LIEPP) de Sciences Po, Paris, France

10-Centre d'études de l'emploi et du travail (CEET, CNAM), Noisy-le-Grand, France

11- Department of Respiratory Diseases, Rennes University Hospital, 35000, Rennes, France

Disclosures: Lescoat A, Lederlin M, Ballerie A, Belhomme N, Cavalin C, Jégo P and Jouneau S have nothing to disclose.

Corresponding author: Alain Lescoat

Department of Internal Medicine, CHU Rennes, South Hospital, 16 bvd de Bulgarie - 35203 RENNES
Cedex 2 - BP 90347

E-Mail : alain.lescoat@chu-rennes.fr

Phone: +33 2 99 26 71 28 fax : +33 2 99 26 71 98

Word count: 593 words/600 ; References 6/6

To the editor:

We read with great interest the article by A Adegunsoye *et al.* (1) recently published in the AJRCCM. Using a rigorous multi-validated protocol, the authors demonstrate that mediastinal lymphadenopathy (MLA) is a strong predictor of clinical outcomes in interstitial lung diseases (ILD), considered as a unique heterogeneous entity including IPF, IPAF, CHP, CTD-ILD and Unclassifiable ILD. Nonetheless, if the results on the strong prognostic value of MLA on survival when all sub-entities are mixed (Figure 1 (1)), could have important implications for patient stratification in the future, considering all types of ILD together may indeed reach its limits when interpreting the results on plasmatic biomarkers. For example, based on their results and those of ongoing trials in IPF, the authors suggest that IL-6 might be protective in fibrotic ILD (1). This statement might be tempered, especially when considering CTD-ILD, since IL-6 may constitute a therapeutic target in Scleroderma-associated ILD, with promising results of Tocilizumab on pulmonary involvement in a recent clinical trial (2). From a pathogenesis and nosological viewpoint, separating each ILD subgroup may therefore remain relevant.

Beyond prognostic and therapeutic considerations, Adegunsoye and colleagues' results may have far-reaching heuristic consequences, and raise the issue of the precise etiology and pathogenesis of MLA in ILD. In their work, obvious causes of MLA were carefully ruled-out since sarcoidosis, drug-toxicity-related ILD and cancers were excluded. Nonetheless, although age and gender were included in the multivariable Cox regression model (Table 2(1)), the possible role of chronic heart failure as a concurrent etiology of MLA (3) as well as a cause of all-cause hospitalization and/or respiratory hospitalization and/or death, cannot be completely excluded. This hypothesis is supported by the significant difference ($p=0.028$) in the prevalence of coronary heart disease between patients with and without MLA (Table 1(1)). This is particularly true when considering the association of MLA with higher pulmonary artery diameter, higher Aorta diameter, male gender, older age and tobacco use.

Although we do not assume that heart failure alone may explain the strong prognostic value of MLA in ILD, exploring the association of MLA with cardiac biomarkers such as NT-ProBNP levels (3) and their respective prognostic values may help to clarify this issue.

From an etiologic viewpoint, this specific focus on MLA may bring back into light neglected causes of ILD with MLA, such as dust exposures. No mention is made of pneumoconiosis in Adegunsoye's work. The higher prevalence of MLA in men (Table 1(1)), in addition with the well-known association between occupational dust exposures and male gender, also highlights this issue. Recent studies have pointed out that the prevalence of crystalline silica exposure in CTD-ILD might be under-evaluated (4). There is growing interest for the involvement of environmental airborne contaminants in ILD of unknown etiologies such as IPF (5) but also in CTD-ILD (4) or other fibrotic ILD like pulmonary alveolar proteinosis (PAP) with fibrotic features (6). Beyond size, location or number, giving a thorough description of MLA, with a specific attention paid to density or calcifications, may offer new insights into the complex relationship between exposure to airborne contaminants and ILD. Histological considerations on MLA in ILD may also help to clarify the immune processes at stake. As recently suggested about PAP of autoimmune origin, *dysimmune* is not synonymous with *idiopathic* (6). Therefore, further studies are needed to better understand the specific etiologies of MLA in ILD of unknown origin. In the end, this could help to refine the current nosological classification of these diseases, and possibly improve the search for a proper cause leading to potential efficient preventive measures.

REFERENCES:

1. Adegunsoye A, Oldham JM, Bonham C, Hrusch C, Nolan P, Klejch W *et al.* Prognosticating Outcomes in Interstitial Lung Disease by Mediastinal Lymph Node Assessment: An Observational Cohort Study with Independent Validation. *Am J Respir Crit Care Med* [online ahead of print] 14 Sept 2018; www.atsjournals.org/doi/abs/10.1164/rccm.201804-0761oc
2. Khanna D, Denton CP, Jhreis A, van Laar JM, Frech TM, Anderson ME *et al.* Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. *Lancet*. 2016 Jun 25;387(10038):2630-2640.
3. Ngom A, Dumont P, Diot P, Lemarié E. Benign mediastinal lymphadenopathy in congestive heart failure. *Chest* 2001; 119(2):653-6
4. Marie I, Gehanno JF, Bubenheim M, Duval-Modeste AB, Joly P, Dominique S *et al.* Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature. *Autoimmun Rev*. 2014 ,Feb;13(2):151-6.
5. Winterbottom CJ, Shah RJ, Patterson KC, Kreider ME, Panettieri RA Jr, Rivera-Lebron B *et al.* Exposure to Ambient Particulate Matter Is Associated With Accelerated Functional Decline in Idiopathic Pulmonary Fibrosis. *Chest*. 2018 May;153(5):1221-1228.
6. Ronsmans S, Nemery B. The presence of autoimmune antibodies in pulmonary alveolar proteinosis does not necessarily imply idiopathic disease. *Lancet Respir Med*. 2018 Sep;6(9):e48.